The Oura sleep tracking lawsuit, filed 20 August 2026 in the US District Court for the Northern District of California, arrives at an awkward moment for the Finnish wearable maker: weeks after it filed to go public at an $11 billion valuation, it now faces a proposed class action alleging that the core feature it sells on is fundamentally misleading.
The case, captioned Surber v. Oura Inc. et al. (case number 3:26-cv-08686), names both Oura Inc. and Oura Health Oy as defendants. It was brought by Clarkson Law Firm on behalf of named plaintiff Madison Surber, who purchased an Oura Ring 4 Gold for approximately $513.68 in May 2025, allegedly after relying on the company’s marketing promises about sleep-staging accuracy.
The complaint seeks more than $5 million in compensation from a class of at least 100 members, and positions Oura at the centre of a nearly $7 billion sleep-tracking market.
What the Oura Sleep Tracking Lawsuit Actually Argues
The complaint’s core allegation is a hardware problem. According to the filing, the Oura Ring contains red and infrared LEDs, green and infrared LEDs, a digital temperature sensor, and an accelerometer. What it does not contain, the complaint argues, are the sensors that clinical sleep measurement actually requires: electrodes for brain waves (EEG), sensors for eye movement (EOG), instruments for muscle tone (EMG), or leads for cardiac electrical activity (ECG).
‘Oura did not just claim to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in,’ the complaint reads, ‘which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do.’
The filing further alleges that Oura acknowledged in its own technical materials that using an Oura Ring is not the same as a polysomnography sleep study, because the device does not measure brain activity or eye movements. The complaint describes those admissions as ‘buried far from the marketing claims that drive sales.’
The lawsuit brings seven legal claims, including fraud by misrepresentation, violations of the California Consumers Legal Remedies Act, the False Advertising Law, the Unfair Competition Law, and breach of express warranty. It calls on Oura to stop advertising the rings as having capabilities they do not deliver, and seeks restitution for consumers who purchased the products based on those claims.
The Numbers Behind the Allegations
The accuracy figures at issue are specific, and they measure different things. Oura’s 95% sleep-staging accuracy figure, which appears on the Oura Ring 5 product page, describes sleep-versus-wake detection: a binary question of whether a given time slice was asleep at all. The company’s earlier 79% figure, drawn from a 2022 company blog post, described agreement with polysomnography across the four sleep stages (wake, light, deep, and REM).
Those are not interchangeable claims. As MDDIOnline reported in its analysis of the dispute, the 95% figure measures a much simpler task than four-stage classification, and Oura confirmed this framing in its own August 2026 response to the lawsuit.
An independent 2025 study published in Nature, cited in the complaint, tested Oura rings across 45 nights from 45 patients and found approximately 53.18% accuracy in identifying sleep stages. The rings underestimated light sleep by 13.84 minutes and deep sleep by 5.98 minutes, and overestimated REM sleep by 31.56 minutes. The researchers cautioned that reasonable average agreement with polysomnography can mask substantial individual-level error.
A separate, Oura-funded 2024 study published in the journal Sensors, conducted at Brigham and Women’s Hospital across 35 healthy adults, found that for sleep-versus-wake detection, sensitivity was at or above 95% for the Oura Ring Gen3 as well as an Apple Watch Series 8 and a Fitbit Sense 2. For distinguishing between sleep stages, the Oura ring’s sensitivity ranged from 76.0% to 79.5%. The study’s first author is reported to be a member of Oura’s Medical Advisory Board and to have received consulting fees from the company.
Ryan Clarkson, co-founder and managing partner at Clarkson Law Firm, framed the stakes in the emailed press release accompanying the filing: ‘When people rely on a device to guide decisions about their health, misinformation cannot be tolerated. People structure their days, interpret the way they feel, and design their lives around inaccurate figures spit out by these devices.’
Oura’s response, reported by Cybernews, was brief: ‘We stand behind our science, research, and accuracy claims. We dispute the allegations in this complaint and intend to defend against them.’ Three days after the filing, the company’s director of health science published a defence of consumer sleep wearables on the Oura blog.
The case will turn on whether the 95% accuracy claim, as Oura framed it, constitutes a material misrepresentation when the number refers to sleep-versus-wake detection rather than the four-stage classification consumers likely understood it to mean. That question is precisely what a federal judge in San Francisco will now have to decide. With an IPO filing already on the table, the timing could hardly be less convenient for Oura’s investors.
